Research Analysts Set Expectations for Curis Q1 Earnings

Curis, Inc. (NASDAQ:CRIS) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Curis in a research report issued on Monday, March 31st. HC Wainwright analyst E. White expects that the biotechnology company will earn ($1.39) per share for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Curis’ current full-year earnings is ($7.12) per share. HC Wainwright also issued estimates for Curis’ Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($2.98) EPS and FY2027 earnings at ($2.87) EPS.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.11. Curis had a negative net margin of 443.35% and a negative return on equity of 923.37%. The company had revenue of $2.70 million during the quarter, compared to the consensus estimate of $2.04 million.

Separately, StockNews.com assumed coverage on Curis in a research report on Saturday, March 29th. They set a “hold” rating for the company.

Curis Price Performance

NASDAQ:CRIS opened at $1.48 on Thursday. Curis has a 12 month low of $1.40 and a 12 month high of $17.49. The firm has a market capitalization of $12.53 million, a PE ratio of -0.19 and a beta of 3.49. The business’s fifty day moving average price is $2.94 and its 200 day moving average price is $3.82.

Institutional Investors Weigh In On Curis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Focused Wealth Management Inc boosted its stake in Curis by 9.5% in the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after acquiring an additional 5,138 shares in the last quarter. CM Management LLC lifted its holdings in shares of Curis by 83.3% in the 4th quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock valued at $673,000 after purchasing an additional 100,000 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Curis by 27.3% in the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 17,820 shares during the period. M28 Capital Management LP boosted its position in shares of Curis by 23.5% in the 4th quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after purchasing an additional 99,108 shares during the period. Finally, Samsara BioCapital LLC purchased a new position in Curis during the 4th quarter worth approximately $607,000. 29.97% of the stock is currently owned by institutional investors and hedge funds.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.